Analyst Ratings For Apollo Endosurgery Inc (NASDAQ:APEN)
Today, Apollo Endosurgery Inc (NASDAQ:APEN) stock received an upgrade by Northland Securities from Under Perform to Market Perform with a price target of $3.00.
There are 2 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Apollo Endosurgery Inc (NASDAQ:APEN) is Hold with a consensus target price of $5.00 per share, a potential 30.21% upside.
Some recent analyst ratings include
- 1/2/2019-Apollo Endosurgery Inc (NASDAQ:APEN) gets upgraded to Market Perform by Northland Securities with a price target of $3.00
- 4/13/2018-Apollo Endosurgery Inc (NASDAQ:APEN) has coverage initiated with a Overweight rating and $8.00 price target
- 7/24/2017-Apollo Endosurgery Inc (NASDAQ:APEN) has coverage initiated with a Buy rating and $11.00 price target
- On 12/26/2018 Stonepine Capital, L.P., Major Shareholder, sold 500,000 with an average share price of $3.00 per share and the total transaction amounting to $1,500,000.00.
- On 11/21/2018 Stonepine Capital, L.P., Major Shareholder, bought 57,430 with an average share price of $3.41 per share and the total transaction amounting to $195,836.30.
- On 11/19/2018 Stonepine Capital, L.P., Major Shareholder, bought 54,200 with an average share price of $3.40 per share and the total transaction amounting to $184,280.00.
- On 11/2/2018 Stonepine Capital, L.P., Major Shareholder, bought 300,000 with an average share price of $5.00 per share and the total transaction amounting to $1,500,000.00.
- On 6/20/2018 Matthew S Crawford, Director, bought 363,500 with an average share price of $5.50 per share and the total transaction amounting to $1,999,250.00.
- On 6/20/2018 Stefanie L. Cavanaugh, CFO, bought 4,545 with an average share price of $5.50 per share and the total transaction amounting to $24,997.50.
- On 6/20/2018 Todd Newton, CEO, bought 72,727 with an average share price of $5.50 per share and the total transaction amounting to $399,998.50.
About Apollo Endosurgery Inc (NASDAQ:APEN)
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Recent Trading Activity for Apollo Endosurgery Inc (NASDAQ:APEN)
Shares of Apollo Endosurgery Inc closed the previous trading session at 3,84 +0,39 11,30 % with 3.45 shares trading hands.